Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
June 01 2023 - 3:05PM
Business Wire
Scientific Advisory Board members bring
significant global expertise in oncology drug and clinical
development
Nuvation Bio Inc. (NYSE: NUVB), a
biopharmaceutical company tackling some of the greatest unmet needs
in oncology by developing differentiated and novel therapeutic
candidates, today announced the formation of a Scientific Advisory
Board. The Scientific Advisory Board will work alongside the
Nuvation Bio management team to advance its pipeline of therapeutic
candidates for some of the most difficult-to-treat cancers.
“We are proud to announce the formation of Nuvation’s Scientific
Advisory Board. The six founding members are oncology drug and
clinical development leaders who have advanced new therapies for
various types of cancers,” said David Hung, M.D., Founder,
President, and Chief Executive Officer of Nuvation Bio. “We look
forward to collaborating with our Scientific Advisory Board as we
continue to study NUV-868, a BD2-selective BET inhibitor, and work
towards submitting an IND for our first drug-drug conjugate (DDC)
clinical candidate by year end.”
The founding members of the Nuvation Bio Scientific Advisory
Board are:
- Wassim Abida, M.D., Ph.D., is the Director of
Translational Research in Prostate Cancer and Associate Attending
Physician of Genitourinary Oncology at Memorial Sloan Kettering
Cancer Center, where his focus is on prostate cancer clinical
investigation, developmental therapeutics, and translational
science. His current research centers on the genomics of prostate
cancer and molecularly-targeted clinical trials, specifically on
DNA repair targeting. Dr. Abida earned his M.D. and Ph.D. at
Columbia University, where he studied mechanisms of regulation of
the p53 tumor suppressor pathway.
- Johann de Bono, M.D., MSc, Ph.D., is the Regius
Professor of Cancer Research and Professor in Experimental Cancer
Medicine at The Institute of Cancer Research (ICR) and Royal
Marsden. He is Head of the Division of Clinical Studies at ICR and
the Director of the Royal Marsden Drug Development Unit, which is
one of the world’s largest Phase 1 clinical trial units for cancer,
run jointly between ICR and The Royal Marsden and The London
Movember Prostate Cancer Centre of Excellence. Dr. de Bono leads
the Prostate Cancer Targeted Therapies team and has also led on
multiple Phase 3 trials that have changed the standard of care for
prostate cancer, including trials of the ICR-discovered drug
abiraterone, cabazitaxel, enzalutamide, and olaparib. He earned his
M.D. and MSc in cancer sciences from the University of Glasgow
Medical School and received his Ph.D. in medical oncology from the
Beatson Institute of Cancer Research.
- Gordon B. Mills, M.D., Ph.D., is the Director of
Precision Oncology and Serial Measurements of Molecular and
Architectural Responses to Therapy (SMMART) trials at the Oregon
Health & Science University (OHSU) Knight Cancer Institute. He
is responsible for the implementation of SMMART, an integrated
program of tumor analysis, decision-making, and implementation of
novel precision oncology trials. Dr. Mills’ research focuses on the
genomics and genetics of breast and ovarian cancers and identifying
and characterizing potential oncogenes and tumor suppressor genes.
He serves on the Scientific Advisory Board of several companies,
including Nuvectis Pharma, PDX Pharma, and Turbine. Dr. Mills
earned his M.D. and Ph.D. in biochemistry and completed his
training in obstetrics and gynecology at the University of
Alberta.
- Mansoor Raza Mirza, M.D., is Chief Oncologist at the
Department of Oncology, Rigshopitalet — the Copenhagen University
Hospital, Denmark and Medical Director of the Nordic Society of
Gynaecological Oncology, Vice-President of the European Society of
Gynaecological Oncology, and past-chairman of the European Network
of Gynaecological Oncological Trial Groups. He has broad experience
in clinical protocol development, trial conduct, and clinical trial
regulations. Dr. Mirza is the author and principal investigator of
several Phase 1, 2, and 3 studies and is a chair/member of the
Independent Data Monitoring Committee of several international
trials. He is a member of the Board of Directors of KaryoPharm,
Metamark Genetics, and Sera Prognostics and is a member of the
Scientific Advisory Board of Allarity Therapeutics. Dr. Mirza
earned an M.D., Diploma in surgery, and Diploma in clinical
oncology from the Pirogov Moscow State Medical Institute and
post-graduate education and certification in radiation and medical
oncology from the University of Southern Denmark.
- Allyson Ocean, M.D., is a Medical Oncologist and
Attending Physician in Gastrointestinal Oncology at New
York-Presbyterian Hospital/Weill Cornell Medical Center, Associate
Professor of Medicine at the Weill Medical College of Cornell
University, and Medical Oncologist at The Jay Monahan Center for
Gastrointestinal Health. She has authored numerous peer-reviewed
articles and abstracts and is an active member of several
professional societies, including the American Society of Clinical
Oncology (ASCO) and American Association for Cancer Research
(AACR). Dr. Ocean is on the Board of Directors of Novocure and the
Scientific Advisory Board of several non-profit organizations. Dr.
Ocean co-founded Let's Win Pancreatic Cancer, an award-winning
non-profit organization and digital platform that connects patients
to promising science and clinical trials. She graduated cum laude
from Tufts University and with AOA honors from the Tufts University
School of Medicine, where she completed her residency in internal
medicine and fellowship in medical oncology at New
York-Presbyterian Hospital/Weill Cornell Medical Center.
- Joyce O’Shaughnessy, M.D., is the Celebrating Women
Endowed Chair in Breast Cancer Research, Baylor University Medical
Center, Texas Oncology and Chair, Breast Cancer Research, US
Oncology Research Network. She focuses her clinical research on
breast cancer treatment, especially in genotype-phenotype
correlations for high-risk breast cancers and immunotherapy for
triple negative breast cancer. Dr. O’Shaughnessy is a member of the
Scientific Advisory Boards of Systems Oncology, Scorpion
Therapeutics, and Allarity Therapeutics. She received her M.D. from
Yale University Medical School, completed her internship and
residency in internal medicine at Massachusetts General Hospital
and concluded a fellowship in medical oncology at the National
Cancer Institute, where she also served as a Senior
Investigator.
About Nuvation Bio
Nuvation Bio is a biopharmaceutical company tackling some of the
greatest unmet needs in oncology by developing differentiated and
novel therapeutic candidates. Nuvation Bio’s proprietary portfolio
includes mechanistically distinct oncology therapeutic product
candidates, each targeting some of the most difficult-to-treat
types of cancer. Nuvation Bio was founded in 2018 by biopharma
industry veteran David Hung, M.D., who previously founded
Medivation, Inc., which brought to patients one of the world’s
leading prostate cancer medicines. Nuvation Bio has offices in New
York and San Francisco. For more information, please visit
www.nuvationbio.com.
Forward Looking Statements
Certain statements included in this press release that are not
historical facts are forward-looking statements for purposes of the
safe harbor provisions under the United States Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
sometimes accompanied by words such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”
“would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,”
“outlook” and similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
These forward-looking statements include, but are not limited to,
statements regarding the potential therapeutic benefit of Nuvation
Bio’s product candidates and the expected timing of an IND filing
for Nuvation Bio’s first DDC clinical candidate. These statements
are based on various assumptions, whether or not identified in this
press release, and on the current expectations of the management
team of Nuvation Bio and are not predictions of actual performance.
These forward-looking statements are subject to a number of risks
and uncertainties that may cause actual results to differ from
those anticipated by the forward-looking statements, including but
not limited to the challenges associated with conducting drug
discovery and initiating or conducting clinical trials due to,
among other things, difficulties or delays in the regulatory
process, enrolling subjects or manufacturing or acquiring necessary
products; the emergence or worsening of adverse events or other
undesirable side effects; risks associated with preliminary and
interim data, which may not be representative of more mature data;
and competitive developments. Risks and uncertainties facing
Nuvation Bio are described more fully in its Form 10-Q filed with
the SEC on May 4, 2023, under the heading “Risk Factors,” and other
documents that Nuvation Bio has filed or will file with the SEC.
You are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date of this
press release. Nuvation Bio disclaims any obligation or undertaking
to update, supplement or revise any forward-looking statements
contained in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230601005843/en/
Nuvation Bio Investors: ir@nuvationbio.com
Nuvation Bio Media: nuvation@argotpartners.com
Panacea Acquisition (NYSE:NUVB)
Historical Stock Chart
From May 2024 to Jun 2024
Panacea Acquisition (NYSE:NUVB)
Historical Stock Chart
From Jun 2023 to Jun 2024